sameAs
HIV entry inhibitors: mechanisms of action and resistance pathwaysSeroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testingNews on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference.Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapyRapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.[Pharmacokinetics, interactions and mechanism of action of maraviroc].Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy.Enfuvirtide, the first fusion inhibitor to treat HIV infection.Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in SpainSensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.Directly acting antivirals against hepatitis C virus.Treatment failure with new hepatitis C drugs.Hepatitis B virus and HIV infection.Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.Hepatitis C therapy with HCV NS5B polymerase inhibitors.Hepatitis B in HIV-infected patients.Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy.Update on hepatitis C virus resistance to direct-acting antiviral agents.High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreementNews on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference.Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing.When is Early Antiretroviral Therapy Early Enough for HIV Remission?Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected.Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV.Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters.New Strategies for a Comprehensive Fight Against HIV Infection using Monoclonal Antibody Therapy.Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc.Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy.Short communication: severe immune suppression in patients infected with R5-tropic HIV-1 strains is associated with increased gp120 net charge at variable regions.Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.The changing face of hepatitis C in the new era of direct-acting antivirals.Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor.HTLV infection in HCV-antibody positive patients in Spain.HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.
P50
Q28296162-F4C34558-12B8-4CA2-B3E1-E892DB50F33FQ28545237-815136FE-5021-4B8A-B663-E6F4EB214C76Q30238499-90C4CDD4-E73C-4FFB-B0E4-A3A82C090D2EQ33962894-B42A87AA-0489-4A1F-9E22-D479B776D6D5Q34437450-1F81209D-4D66-40FB-B10C-F6E63B2F7CFEQ34474966-4C9EE2F6-AF35-4EFF-AFD7-E4AD953D069DQ34602894-2BDD35AB-1AE8-4670-8E5B-C07E2B474AC2Q34636796-53EDB387-037F-424B-96CA-80849021A0F7Q35838609-4A296697-3A06-4BD8-820E-DC380A305FD7Q36319260-0CF07651-20D3-4640-A155-AF9B28D6104EQ36497842-CC446DBB-2449-4EF9-9D41-B623F573E0E3Q36743921-06C546FC-3E03-4FC6-94FD-29FBCDA87BE5Q36826759-E79403F4-8E91-49A7-B270-5AF9FC7267DDQ37788958-6170E7B7-8F61-4516-87A8-46C245612120Q37886406-E6EE73CB-3577-4D83-B0DE-086536A21C75Q37975543-79F39D58-96BE-469A-B677-9AFD07666EB4Q38023750-9BE48339-D837-4F8D-9B4E-8E1BD2F6438EQ38029538-EEC9789A-43CB-4B4C-9BE5-60DC1519C556Q38101955-9E4EDAAA-31DD-4F87-B910-88A4D990E8B1Q38125742-3E3D7947-D5CC-4B98-ABAA-5C3843C56F04Q38126219-4C90B351-6C7C-4CA9-AFBA-DBF1C56497BFQ38218790-1ACDAE4C-D549-4238-99AF-A8CA7A9D9518Q38285227-AD288078-4532-4011-B04A-32A95B93D5E6Q38652490-8D1AC63F-275A-4DB1-8427-A41BD5556322Q38719511-36FC59FF-DABC-434B-A8B4-9D6483565426Q38769148-B57EE66A-BD17-4D25-90EC-7DA059601B17Q38769154-4537693B-2493-48FF-A323-36DBECD95644Q38820854-2C64E684-8A82-4831-B384-DFB34085223AQ38836657-0384A500-9E85-45CC-9658-A404E49C45FDQ38946506-099A8B2B-6ED4-4C0F-BB7C-79160B247178Q38966299-DAEB1643-7668-4C64-BAF9-DAE5603E00EAQ38976724-D6E5C4BB-C8E4-44FE-B6AC-9E759CD2645DQ39179620-002AA1BC-3D21-4AED-B3E3-9310FBF68BB6Q39365907-C78C7070-8244-4462-B9ED-997BB609693FQ39443071-EC0CD109-7253-482C-9F14-184F0F3C4961Q39443078-864EBE73-108A-423F-A085-3D1BF61A1E1CQ39521142-8A9C96D7-0F06-42C7-9113-2B0DC734902AQ39529760-9545D1EE-07DE-4B35-8D0F-DBBE48459BC4Q39533345-85BA02BE-7DBF-4600-9607-7C0A0DBF3A29Q39533357-E44F9C69-A404-4BC8-B58B-892EBF68D1F3
P50
description
Spaans virologe
@nl
Spanish virologist
@en
spanische Forscherin und Virologin
@de
viróloga española
@ast
viróloga española
@es
name
Eva Poveda
@ast
Eva Poveda
@ca
Eva Poveda
@en
Eva Poveda
@es
Eva Poveda
@fr
Eva Poveda
@ga
Eva Poveda
@nl
Eva Poveda
@sl
Eva Poveda
@sq
type
label
Eva Poveda
@ast
Eva Poveda
@ca
Eva Poveda
@en
Eva Poveda
@es
Eva Poveda
@fr
Eva Poveda
@ga
Eva Poveda
@nl
Eva Poveda
@sl
Eva Poveda
@sq
altLabel
EVA POVEDA
@en
prefLabel
Eva Poveda
@ast
Eva Poveda
@ca
Eva Poveda
@en
Eva Poveda
@es
Eva Poveda
@fr
Eva Poveda
@ga
Eva Poveda
@nl
Eva Poveda
@sl
Eva Poveda
@sq
P19
P21
P27
P31
P373
Eva Poveda
P496
0000-0003-4835-9875
P569
1975-07-22T00:00:00Z